Table 3.
Abomasal fluid pharmacokinetic parameters (mean ± SD, n = 4) for flubendazole (FLBZ) and its reduced metabolite (R-FLBZ) obtained after the intraruminal (i.r.) administration of FLBZ (3.8 mg/kg) formulated as a cyclodextrin-based solution (FLBZ-CDs) or a carboximethylcelullose suspension (FLBZ-CMC) to sheep (Experiment 1)
| PHARMACOKINETIC PARAMETERS |
FLBZ |
R-FLBZ |
||
|---|---|---|---|---|
| FLBZ-CDs i.r. treatment | FLBZ-CMC i.r. treatment | FLBZ-CDs i.r. treatment | FLBZ-CMC i.r. treatment | |
| Cmax (μg/mL) |
0.11 ± 0.01 |
0.16 ± 0.06 |
0.43 ± 0.13 |
0.67 ± 0.40* |
| Tmax (h) |
10.5 ± 3.00 |
9.75 ± 2.87 |
12.8 ± 3.77 |
12.0 ± 0.00 |
| AUC0-t (μg.h/mL) |
2.95 ± 0.66 |
3.63 ± 1.05 |
12.0 ± 5.01 |
21.7 ± 15.8 |
| T½el (h) |
12.3 ± 5.99 |
9.83 ± 4.23 |
16.2 ± 7.54 |
16.3 ± 5.95 |
| MRT (h) | 23.0 ± 8.28 | 20.4 ± 5.23 | 30.0 ± 12.1 | 31.2 ± 8.80 |
T½abs/for: FLBZ absorption or metabolite formation half life; Cmax: peak plasma concentration; Tmax: time to the Cmax; AUC0-t: Area under the plasma concentration vs. time curve from 0 to the detection time; T½el: elimination half-life; MRT: mean residence time (obtained by non-compartmental analysis of the data). *Significantly different from the FLBZ-CDs i.r. treated group at P < 0.05.